KPKrishna Pandey

Krishna Pandey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Krishna Pandey has a total of 436 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic Caveats and Clinical Pitfalls in the Overlap of Leprosy and Para-Kala-Azar Dermal Leishmaniasis

    by Rishikesh Kumar, Devendra Prasad Yadav, Sanjay Kumar Chaturvedi, Krishna Pandey

    "Diagnostic Caveats and Clinical Pitfalls in the Overlap of Leprosy and Para-Kala-Azar Dermal Leishmaniasis" published on 07 Oct 2026 by The American Society of Tropical Medicine and Hygiene.

  • Open Access

    Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis

    by Wan-Yu Chu, Om Prakash Singh, Shyam Sundar, Krishna Pandey, Pradeep Das, Dinesh Mondal, Brima Musa Younis, Ahmed Mudawi Musa, Abhishek Kumar Singh, Deepak Kumar Verma, et al.


  • Open Access

    The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

    by Sauman Singh-Phulgenda, Prabin Dahal, Brittany J. Maguire, Jorge Alvar, Fabiana Alves, Mitali Chatterjee, Carlos Costa, Simon L. Croft, Philippe J. Guerin, Dinesh Mondal, et al.

    Background: Visceral leishmaniasis (VL) is one of the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO). The disease is currently in the elimination phase in the Indian subcontinent (ISC) and being targeted for elimination by 2030 in East Africa (EA). Maintaining the necessary financial and political commitments to achieve and sustain the current elimination efforts remains challenging. As with other NTDs, VL research is constrained by limited funding, and drug development has relied largely on partnerships between not-for-profit organisations and the pharmaceutical industry. Conducting robust clinical studies remains difficult, and therapeutic innovations have been limited. However, re-use of existing data offers an untapped opportunity to generate new evidence. Methods: We describe the process of developing a global VL research agenda and the establishment of an individual participant data (IPD) platform at the Infectious Diseases Data Observatory (IDDO). Key steps included a systematic scoping review of VL clinical trials, consultations with the Scientific Advisory Committee, expert and public reviews, and implementation of an equitable governance framework to harmonise and share IPD. Results: The VL research agenda, finalised in 2019, identified priority methodological and clinical questions suited to IPD analyses. The IDDO VL platform currently hosts harmonised data from nearly 15,000 patients across more than 50 studies (VL and post-kala-azar dermal leishmaniasis, PKDL). The platform is an inclusive resource guided by an equitable governance framework and provides a critical asset to support new evidence generation and can serve as a historical data to support accelerated drug development. Conclusions: The development of a global VL research agenda has provided an inventory of priority research questions of public health importance. A shared IPD platform aligned with this agenda was developed to complement ongoing global efforts. In addition, such a platform can accelerate secondary evidence generation, support methodological innovation and inform future trial designs and policy. Sustained collaboration and investment are needed to maximise the scientific and public health value of data re-use in VL and PKDL.


  • Bridging the gap in tuberculosis care: A mixed-methods analysis of patient safety challenges and solutions in India

    by Anakha Saji, Priyanka Guha, M.S. Revathy, Abhik Sen, Krishna Pandey, Sameer Dhingra


  • Open Access

    A clinico-epidemiological study, assessing possible predictors of mortality and health-related quality of life for people living with visceral leishmaniasis – human immune virus (VL-HIV) co-infection in a high burden kala-azar endemic state of India: a descriptive cross-sectional study

    by Niyamat Ali Siddiqui, Dhruv Kumar Pandey, Ashish Kumar Singh, Sanjay Kumar Sinha, Mohd. Zahid Ansari, Rishikesh Kumar, Biplab Pal, Vidya Nand Rabi Das, Rajatashuvra Adhikary, Saurabh Jain, et al.

    Visceral leishmaniasis–human immunodeficiency virus (VL-HIV) co-infection has emerged as a serious concern, which could adversely affect the VL elimination efforts of the country. These patients have a poor VL therapeutic success rate, more drug-related toxicity, and relapses resulting in high mortality. Despite the emerging pattern of VL-HIV co-infection, there have been limited studies analyzing the presentation of VL-HIV co-infection in Bihar, India. The present study investigated the clinico-epidemiological features, predictors of mortality, and quality of life for people living with VL-HIV co-infection. A cross-sectional study was conducted, using retrospective data on VL-HIV cases from 2018 to 2020. A semi-structured questionnaire was used for data collection. Data analysis was done, using the IBM SPSS statistics v22. Our study included a large sample of 222 VL-HIV cases, of these one-fifth of the patients (47; 21%) had died. A highly statistically significant difference (P < 0.0001) in mortality was observed between males (38; 80.9%) and females (9; 19.1%). The death occurred rapidly within a mean duration of 6.7 months (95% CI: 5.4–8.1) after VL diagnosis. A highly statistically significant difference (P < 0.0001) was observed between individuals who had stopped anti-retroviral therapy (ART) (36; 76.6%) and those who were taking ART regularly (11; 23.4%) in terms of mortality. The primary predisposing factor observed was heterosexual behavior, which accounted for 113 cases (88.3%). In most of the cases (95.3%), the diagnosis was done at tertiary care centers and not in their home district. The majority of VL cases (101; 78.9%) were treated with multiple doses of liposomal amphotericin B. Out of 128 VL-HIV cases, 120 (93.7%) were declared cured of VL after completing treatment. Approximately 47 cases (36.7%) experienced more than two VL relapses. A significant difference was observed for gender and income per month in the environmental health domain specifically. The present study documents a time gap between the initiation and cessation of ART, as well as the duration from VL treatment to death. It suggests that regular adherence to ART may have a significant impact on reducing mortality and relapses. Therefore, a comprehensive people-centric approach for specific groups must be adopted for VL-HIV patients. Additional epidemiological studies on VL-HIV co-infection are warranted.


  • Open Access

    Antirelapse therapy for visceral leishmaniasis in immunocompetent population and diagnostic dilemmas in therapeutic assessment in India

    by Rishikesh Kumar, Krishna Pandey

    Visceral leishmaniasis (VL), a severe parasitic infection caused by Leishmania species, presents a significant challenge due to its potential for relapse despite treatment. This review aims to rationalize antirelapse therapies for VL and address diagnostic dilemmas encountered in therapeutic assessment. By evaluating current treatment strategies, examining relapse mechanisms, and highlighting diagnostic challenges, we aim to provide a comprehensive understanding of effective management and assessment of VL relapse.

  • Open Access

    Assessment of quality of life in visceral leishmaniasis patients coinfected with HIV: a comparative study in Bihar, India

    by Ram Pund, Gopal Vishwas, Major Madhukar, Krishna Pandey, Sameer Dhingra

    This study was aimed to evaluates the quality of life using WHOQOL-BREF in VL patients co-infected with HIV in Bihar, India. This cross-sectional study enrolled 240 participants: 60 HIV-VL co-infected, 60 HIV, 60 VL and 60 healthy individuals. Socio-demographic data and QOL assessments used the Hindi WHOQOL-BREF questionnaire. The data were compared using the chi-square test, One-Way ANOVA followed by Tukey's post-hoc Test. Generalised linear regression was performed for analyses of predictors of QOL, as well as the socio-economic status was determined by using the Modified Kuppuswamy socio-economic Scale 2022. HIV-VL co-infected patients reported significantly lower QOL scores across all domains (physical, psychological, social relationships, and environmental) compared to healthy individuals (p < 0.05). Notably, psychological (12.17 ± 1.17), social relationship (5.90 ± 1.16), and environmental (14.10 ± 1.68) domains were severely impacted in HIV-VL coinfection in contrast to HIV (p < 0.05) and VL (p < 0.05). HIV-VL co-infection profoundly affects quality of life, emphasizing the need for targeted interventions addressing psychological, social and environmental well-being. Future research should prioritize strategies improving QOL and assessing long-term treatment effects in HIV-VL co-infection.


  • Treatment Outcomes of Single-Dose Liposomal Amphotericin B–Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India

    by Niyamat Ali Siddiqui, Mohd. Zahid Ansari, Sanjay Kumar Sinha, Biplab Pal, Ashish Kumar Singh, Subhankar Kumar Singh, Roshan Kamal Topno, Vidya Nand Rabi Das, Krishna Pandey

    : An assessment of the treatment outcomes of single-dose liposomal amphotericin B, implemented in 2010, had not been conducted until this study. This prospective cross-sectional study encompassed 527 cases, comprising 470 (89%) cases of visceral leishmaniasis (VL) and 57 (11%) cases of post–kala-azar dermal leishmaniasis (PKDL). The male proportion was higher (55% for VL), and the mean (±SD) age was 39.2 (±33.9) years. Among VL cases (426) treated with single-dose liposomal amphotericin B, 402 cases were cured at the 6-month follow-up, resulting in a cure rate of 95%, whereas fewer than 1% (0.9%) experienced unsuccessful outcomes and 4.1% faced relapse. A statistically highly significant difference in treatment outcomes (successful versus unsuccessful) was observed between males and females (P = 0.0005). Males had higher odds of successful outcomes compared with females, with an odds ratio of 5.03 (95% CI: 1.84–13.74). Those aged ≤23 years had higher odds of successful outcomes than unsuccessful outcomes, with an odds ratio of 6.82 (95% CI: 2.29–20.33). Patients with PKDL had a mean (±SD) age of 28.5 (±10.6) years, with 63% being male. Among the 57 PKDL cases, 21 (37%) had been treated with single-dose liposomal amphotericin B, whereas others had received alternative drugs. The median duration of PKDL development for single-dose liposomal amphotericin B was significantly shorter (14.5 months), with a statistically significant difference (P <0.001) compared with other drugs. The current treatment strategy necessitates continuous close monitoring and reviews to ensure consistent and improved outcomes.


  • Epidemiological determinants and quality of life in PLHIV patients with tuberculosis in Bihar State, India

    by Rajat Mishra, Gopal Vishwas, Tukaram Kendre, Priyanka Guha, Krishna Murti, Krishna Pandey, Sameer Dhingra


  • Open Access

    Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform

    by Sauman Singh-Phulgenda, Rishikesh Kumar, Prabin Dahal, Abdalla Munir, Sumayyah Rashan, Rutuja Chhajed, Caitlin Naylor, Brittany J. Maguire, Niyamat Ali Siddiqui, Eli Harriss, et al.

    Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL endemic areas. We conducted a systematic scoping review to assess the characteristics of published PKDL clinical studies, understand the scope of research and explore the feasibility and value of developing a PKDL individual patient data (IPD) platform. A systematic review of published literature was conducted to identify PKDL clinical studies by searching the following databases: PubMed, Scopus, Ovid Embase, Web of Science Core Collection, WHO Global Index Medicus, PASCAL, Clinicaltrials.gov, Ovid Global Health, Cochrane Database and CENTRAL, and the WHO International Clinical Trials Registry Platform. Only prospective studies in humans with PKDL diagnosis, treatment, and follow-up measurements between January 1973 and March 2023 were included. Extracted data includes variables on patient characteristics, treatment regimens, diagnostic methods, geographical locations, efficacy endpoints, adverse events and statistical methodology. A total of 3,418 records were screened, of which 56 unique studies (n = 2,486 patients) were included in this review. Out of the 56 studies, 36 (64.3%) were from India (1983–2022), 12 (21.4%) from Sudan (1992–2021), 6 (10.7%) were from Bangladesh (1991–2019), and 2 (3.6%) from Nepal (2001–2007). Five (8.9%) studies were published between 1981–1990 (n = 193 patients), 10 (17.9%) between 1991–2000 (n = 230 patients), 10 (17.9%) between 2001–2010 (n = 198 patients), and 31 (55.4%) from 2011 onwards (n = 1,865 patients). Eight (14.3%) were randomised clinical trials, and 48 (85.7%) were non-randomised studies. The median post-treatment follow-up duration was 365 days (range: 90–540 days) in 8 RCTs and 360 days (range: 28–2,373 days) in 48 non-randomised studies. Disease diagnosis was based on clinical criterion in 3 (5.4%) studies, a mixture of clinical and parasitological methods in 47 (83.9%) and was unclear in 6 (10.7%) studies. Major drugs used for treatment were miltefosine (n = 636 patients), liposomal amphotericin B (L-AmB) (n = 508 patients), and antinomy regimens (n = 454 patients). Ten other drug regimens were tested in 270 patients with less than 60 patients per regimen. Our review identified studies with very limited sample size for the three major drugs (miltefosine, L-AmB, and pentavalent antimony), while the number of patients combined across studies suggest that the IPD platform would be valuable. With the support of relevant stakeholders, the global PKDL community and sufficient financing, a PKDL IPD platform can be realised. This will allow for exploration of different aspects of treatment safety and efficacy, which can potentially guide future healthcare decisions and clinical practices. Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which mostly manifests after successful treatment of visceral leishmaniasis (VL) and is characterised by macular, papular, nodular, erythematous, or polymorphic rashes. PKDL is a public health problem in VL endemic areas, as recent infectivity studies show that L. donovani parasites can be found in PKDL lesions and remain infectious to sandfly vectors. There are numerous gaps in our existing knowledge of PKDL, including its pathology, immunology, and risk factors associated with therapeutic outcomes. Currently recommended treatments are either expensive (liposomal amphotericin-B), have raised safety concerns (especially for antimony regimens), or require long treatment duration (e.g. miltefosine). In order to scope the measure of evidence supporting therapeutic efficacy recommendations for PKDL patients, we conducted a systematic literature review. Our systematic review identified 56 PKDL studies describing 2,486 patients, with a majority of the studies (31 studies and 1,865 patients) published from 2010 onwards. The Infectious Diseases Data Observatory (IDDO) already have an established data platform for VL, and the IDDO VL data platform currently hosts a critical mass of data from efficacy trials in VL conducted over the past 20 years. Based on the identified volume of data, with a substantial number of studies being relatively recent, we believe that the establishment of a PKDL data platform is feasible. Creating a platform to facilitate the sharing of the datasets would enable in-depth IPD meta-analyses with existing data to address several knowledge gaps of PKDL and guide future research priorities. With the help of relevant stakeholders, the global PKDL community and sufficient resources, a PKDL data platform can be realised and help address key research gaps.